Ablynx [Euronext Brussels: ABLX], announced today that it has been awarded a grant worth EUR1.2 million by the Flemish agency for Innovation by Science and Technology (IWT). The grant supports Ablynx in accelerating the development of its Nanobody-based programme, ALX-0061, into clinical development for the treatment of autoimmune and inflammatory diseases. ALX-0061 binds to the IL-6 receptor (IL-6R). It has a high potency and demonstrated a favourable pharmacodynamic (PD), pharmacokinetic (PK) and safety profile in pre-clinical testing compared with the benchmark molecule… (Source: Health News from Medical News Today)
Further information:
Related posts:
- Arcadia Biosciences Receives $855,500 Grant To Fund Next-Stage Development Of Wheat With Reduced Celiac Disease Potential
- VCU Massey Cancer Center Receives NIH Grant
- Keystone Symposia awarded $1.37 million, 5-year NIH grant to fund ongoing diversity efforts
- Michael J. Fox Foundation awards Mayo Clinic researcher grant to advance Parkinson’s disease research
- ACF Announces The Availability Of $42 Million In Competitive Grant Funding For Native American Communities And Organizations
Posted in